Pursuing therapies against some of the most intractable cancer targets.
Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.
Exploring the therapeutic potential of small molecules that modulate the c-Myc oncoprotein
This company is a spin-out from the 2015 project, Exploring the therapeutic potential of small molecules that modulate the c-Myc oncoprotein.
Studying cancer in context to stop its growth
Kronos Bio, founded by Associate Professor Angela Koehler, studies the complex signaling networks of cancer cells to find new drug targets.